Many evidence indicates that impaired functionality of the APP machinery in tumor cells, in addition to causing a change in the repertoire of antigens presented on the cell surface, results in a change in the level of tumor-infiltrating CD8+ T cells and the response to ICI-based therapy. The gene discussed is APP; the disease is neoplasm.